A phase 2 study, multicenter, open label trial of R1415 (erlotinib hydrochloride) in patients with advanced, metastatic or recurrent non-small cell lung cancer.(JO16565)
Phase 2
- Conditions
- Advanced or metastatic or recurrent non-small cell lung cancer
- Registration Number
- JPRN-jRCT2080220076
- Lead Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
patients with advanced/metastatic or recurrent NSCLC (stage IIIB or IV) who have failed at least one previous platinum chemotherapy regimen.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method